Relationship between T cells, dendritic cells could prevent organ rejection

Study into the link between T cells and dendritic cells could lead to reduced rates of organ rejection in transplant patients.

A worldwide team lead by researchers at the University of Pittsburgh School of Medicine studied just how T cells work in the rejection of transplanted organs in the receiver’s body. When immunosuppressive drugs are not taken, the T cells in the body attack the new organ when activated. Researchers set out to study just how these cells become activated and found a way to stop the activation, which has the potential for researchers to develop a new method for preventing the rejection of donor organs.

When studying T cell activation in mice, the researchers concluded that dendritic cells become activated when come into contact with T cells. In mice with kidney and spleen transplants, the donor dendritic cells were being replaced by the organ recipient’s dendritic cells. This replacement of dendritic cells promoted the activation of T cells within the transplant and increased the rate of organ rejection.

"We demonstrated that dendritic cells not only exert a key role as antigen-presenting cells in graft-draining lymphoid organs, but also play a critical function within the transplanted organs," wrote co-author Adrian E. Morelli, MD, PhD, et al. "Our study indicates that eliminating transplant-infiltrating dendritic cells reduces proliferation and survival of T cells within the graft with the consequent prolongation of transplant survival."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.